STM publisher Elsevier has announced enhancements to Reaxys Medicinal Chemistry that address the critical workflow and data challenges of early drug discovery. Improved discoverability and usability features for Reaxys Medicinal Chemistry, combined with Elsevier's ability to integrate in-house proprietary data, will significantly improve the efficiency of a variety of data-intensive tasks such as in-silico screening.
Establishing reliable compound and bioactivity data for hit identification, hit-to-lead and lead optimisation during the drug development process is time-consuming and resource intensive. The latest enhancements available from Elsevier solutions make it easier for chemists to identify chemical entities with similar structures across multiple content sources. Users now have a variety of possibilities for retrieving high-quality data for in-silico screening and phenotype screening, offering a faster, more cost-effective and accurate alternative to conventional laboratory-based lead optimization research.
Reaxys Medicinal Chemistry includes access to the world's largest database of compound bioactivity. It contains 25 million bioactivity data points making it a comprehensive single source for detailed and high-quality information on small molecules.
Enhancements include: improved content discoverability with the addition of new bio-taxonomies; efficient search with "Ask Reaxys" natural language search technology; new filters for the heatmap; and better workflow integration.
Existing Reaxys Medicinal Chemistry customers were upgraded to the latest version on June 30, 2015.
